AMGN

Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests

Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Ac

Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy.

Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas

General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. Implementation of PL 119-21. Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections.

IRA, drug pricing in federal programs, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, drug pricing in federal programs federal budget issues

Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.

Issues related to health access. PBM reform. Most-Favored-Nation pricing for pharmaceuticals. 340B.

Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. 340B Program issues.

H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019 Issues related to health care research